喉鳞癌瘤内微血管及微淋巴管形态计量研究及临床意义

目的:研究喉鳞癌瘤内微血管和微淋巴管形态、分布、密度,以及相关临床意义。方法:采用5’-Nase-AlPase双重酶组织化学法和HE染色对40侧喉鳞癌标本冰冻切片进行研究。结果:光镜下微血管呈蓝色,微淋巴管呈棕色。除转移组微血管密度显著高于未转移组外,与其余临床指标均未见相关性。结论:瘤内微血管密度与淋巴转移有明显相关,而微淋巴管密度未发现明显临床意义,其机制待深入研究。     

枕下-颞下联合入路颞骨良性肿瘤切除术-附3例报告

目的:介绍枕下-颞下联合入路切除颞骨良性肿瘤的方法及体会。方法:对3例颞枕骨化纤维瘤、颞骨纤维异常增殖症、颞骨血管瘤的巨大颞骨良性肿瘤,均采用枕下-颞下联合入路(倒钩形切口)。辅以显微外科技术进行手术摘除肿瘤。结果:3例均基本完整切除肿瘤,无颅内外感染、脑脊液漏、迷路及颅神经损伤等并发症,经术后随访1.5年～2年未发现肿瘤复发。结论:采用枕下-颞下联合入路切除颞枕骨良性肿瘤可获理想的暴露,最大范围切除肿瘤,可避免损伤毗邻的颅神经、血管以及内耳结构,值得推广。     

阿佐塞米合成工艺的研究

目的：对阿佐塞米合成工艺进行研究。方法：以2-氟-4-氯苯甲酸为起始原料合成阿佐塞米粗品用80％乙醇加活性炭脱色重结晶在60℃以下真空干燥后所得白色结晶性粉末阿佐塞米。结果：总收率为22％，mp：222．7与文献接近。结论：以此工艺合成阿佐塞米是可行的。     

Increased levels of intercellular adhesion molecules and vascular cell adhesion molecules in pre-eclampsia

Objective To investigate the correlation between soluble forms of the intercellular adhesion molecule (SICAM-1) and vascular cell adhesion molecule (sVCAM-1) and the severity of pre-eclampsia or its possible consequences for fetal growth.
Design Prospective observational study.
Setting Institute of Medical Genetics, University of Oslo, Department of Medical Genetics and Haematological Research Laboratory, Ullevål University Hospital; and the Department of Obstetrics and Gynaecology, The National Hospital, Oslo, Norway.
Participants Seventy-six women with normotensive pregnancies and 157 women with pre-eclampsia divided into three subgroups: mild, severe and pre-eclampsia with fetal growth retardation.
Methods ELISA-measurements of plasma SICAM-1 and sVCAM-1 were performed in a group of healthy pregnant normotensive women and three groups of women with varying degrees of pre-eclampsia.
Results SICAM-1 concentrations were higher in the pre-eclampsia group compared with the control group, but this difference was not statistically significant. Plasma concentrations of sVCAM-1 were significantly greater ( P < 0.0001) in all pre-eclampsia subgroups (835.34, 855.25 and 964.05 ng/mL) compared with the control group (667.62 ng/mL). Within the pre-eclampsia group, plasma concentration of sVCAM-1 was significantly higher in the subgroup exhibiting fetal growth retardation ( P = 0.03) compared with mild pre-eclampsia.
Conclusion The observed increases in plasma concentrations of sVCAM-1 suggest that measurements of this adhesion molecule may be useful in monitoring pregnancies with respect to the development of pre-eclampsia or fetal growth retardation.     

Consensus statement on the live organ donor

The Authors for the Live Organ Donor Consensus Group

JAMA. 2000;284:2919-2926.

Objective  To recommend practice guidelines for transplant physicians, primary care providers, health care planners, and all those who are concerned about the well-being of the live organ donor.

Participants  An executive group representing the National Kidney Foundation, and the American Societies of Transplantation, Transplant Surgeons, and Nephrology formed a steering committee of 12 members to evaluate current practices of living donor transplantation of the kidney, pancreas, liver, intestine, and lung. The steering committee subsequently assembled more than 100 representatives of the transplant community (physicians, nurses, ethicists, psychologists, lawyers, scientists, social workers, transplant recipients, and living donors) at a national conference held June 1-2, 2000, in Kansas City, Mo.

Consensus Process  Attendees participated in 7 assigned work groups. Three were organ specific (lung, liver, and kidney) and 4 were focused on social and ethical concerns (informed consent, donor source, psychosocial issues, and live organ donor registry). Work groups' deliberations were structured by a series of questions developed by the steering committee. Each work group presented its deliberations to an open plenary session of all attendees. This information was stored and shaped into a statement circulated electronically to all attendees for their comments, and finally approved by the steering committee for publication. The term consensus is not meant to convey universal agreement of the participants. The statement identifies issues of controversy; however, the wording of the entire statement is a consensus by approval of all attendees.

Conclusion  The person who gives consent to be a live organ donor should be competent, willing to donate, free from coercion, medically and psychosocially suitable, fully informed of the risks and benefits as a donor, and fully informed of the risks, benefits, and alternative treatment available to the recipient. The benefits to both donor and recipient must outweigh the risks associated with the donation and transplantation of the living donor organ.

     

喉癌患者血清可溶性白细胞介素-2受体和肿瘤坏死因子水平的研究

应用单克隆、多克隆双抗体夹心ELISA检测了35例喉鳞癌患者的血清可溶性白细胞介素2受体(sIL-2R)和肿瘤坏死因子(7NF-α)水平。结果显示:喉癌患者sIL-2R水平较良性组或正常人显著升高(P<0.001),与喉癌临床分期、临床分型及淋巴结转移密切相关;喉癌患者7NF-α水平只有Ⅳ期显著高于良性组或正常人(P<0.05).提示:血清sIL-2R水平检测可作为喉癌诊断的一项辅助指标,并有助于了解喉癌的临床进程及生物学行为(如淋巴结转移等);TNF-α在介导喉癌的恶病质方面起重要作用。本文还探讨了血清sIL-2R水平在喉癌中升高的机理。     

颞骨内微型面神经鞘瘤病理研究

目的探讨颞骨内微型面神经鞘瘤的原发部位和病理行为。方法用光镜对８１５人（１５２６侧）颞骨连续切片进行面神经颞骨内全程组织病理学观察。结果发现未诊断的无症状微型ＡｎｔｏｎｉＡ型面神经鞘瘤１５人（１７耳），占１．８４％。依其病理行为特征分为外生性（１３耳，起自面神经管裂处神经束膜，并向管外生长）和内生性（４耳，起自面神经主干）两种类型。肿瘤起自迷路段者２耳，水平段１２耳，第二膝段１耳，垂直段２耳。结论将颞骨内面神经鞘瘤分为内生性和外生性两种类型有重要的病理和临床意义，有助于手术目的的确定和手术方法的设计     

Survival rates for primary malignant brain tumours in Europe

In the framework of EUROCARE, a concerted action between 45 population-based cancer registries, in 17 European countries, survival of patients with primary malignant brain tumours was investigated. Survival analysis was carried out on 16 268 patients diagnosed between 1985 and 1989 and followed-up for at least 5 years. The mean European age-standardised 5-year relative survival was 17% in men and 20% in women, with minimal intercountry variations, except for markedly lower rates in Scotland, Estonia and Poland. The age-specific analysis showed a relatively uniform survival in patients aged more than 65 years at diagnosis, but there were more marked intercountry differences in younger patients. In the 15–44 year age group (25% of the total study population) 5-year relative survival ranged between 55% (Finland and Sweden) and 27% (Poland). Generally, survival decreased with increasing age at diagnosis. The analysis of a temporal trend in survival was carried out on a subset of registries with available data from 1978–1989. Overall, there was an increase in survival over the considered study period, mostly confined to 1-year survival, suggesting that it was mostly related to improved diagnostic techniques. The most important survival increase occurred in the younger patients, both for 1- and 5-year survival, suggesting that younger patients have less biologically aggressive tumours, benefiting from the combined effect of diagnostic accuracy and effective therapies. The most marked survival increase was seen in England and Denmark, countries with low survival rates at the beginning of the study period, whereas in Finland and Germany, where survival was relatively high to begin with, no important temporal trend was seen.